Clontech: CELLINK enters a collaborative research program with Takara Bio

CELLINK and Takara Bio Europe AB will collaborate to evaluate bioprinting of CELLINK's Bioink with Takara's cells for insulin secretion by iPS derived beta cells. The project aim is to commercialize technology where both parties would benefit from the developed application of the combined technology. The end product would be a cell-specific bioink optimized for Takaras iPS beta cells to accelerate the tissue maturation in 3D culture. The project is now initiated, and potential commercialization of results would reach the market during 2018. About Takara Bio Europe AB Takara Bio